1
Registered trials
0
Recruiting
1
Unique sponsors
1
Unique IMPs
1
Commercial trials
Drug classes (ATC)
S
Ophthalmology/ENT (ATC S)
1
Mechanism of action (INN-stem analysis)
Monoclonal antibody
1 substance
Phase II:
1
Phase II
1 trial-
EndedSamsung Bioepis Co. Ltd. CommercialRANIBIZUMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Samsung Bioepis Co. Ltd. | Commercial | 1 | Phase II | 0 |
New trials by year
2026
1